The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | NICHE-2: nivolumab and ipilimumab in non-metastatic MSI-high colon cancer
John Strickler, MD, Duke Cancer Institute, Durham, NC, gives an overview of the NICHE-2 trial (NCT03026140), which assessed immunotherapy for non-metastatic MSI-high colon cancer. Traditionally treated with resection and adjuvant chemotherapy, patients in the trial received nivolumab and ipilimumab. A promising 3-year disease-free survival rate was reported and the regimen was well-tolerated. The findings highlight the potential of the combination to become an emerging standard of care for this group of patients. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
